# Neoadjuvant Pembrolizumab in Patients With Stage IIb/c Melanoma

> **NCT07349303** · PHASE2 · RECRUITING · sponsor: **Vastra Gotaland Region** · enrollment: 30 (estimated)

## Conditions studied

- Melanoma (Skin Cancer)

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07349303
- **Lead sponsor:** Vastra Gotaland Region
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-15
- **Primary completion:** 2029-05-15
- **Final completion:** 2031-05-15
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07349303

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07349303, "Neoadjuvant Pembrolizumab in Patients With Stage IIb/c Melanoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07349303. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*